Dendrite Clinical Systems’ unique and innovation clinical software is been employed for a new innovative Quality Improvement, Patient Safety and Research trial that is seeking to improve the quality of care delivered to patients requiring hip or knee joint replacement surgery by introducing two complimentary care-bundles for mild anaemia and Methicillin Sensitive Staphylococcus aureus (MSSA) into routine clinical practice.
Dendrite Clinical Systems is to install its “Intellect System” to track outcomes of cardiothoracic surgery at the Cardiothoracic and Vascular Intensive Care and High Dependency Unit, Auckland City Hospital, Auckland, New Zealand. The establishment of a Dendrite system at the unit will improve the quality of data and coding quality by creating effective clinical data entry and reporting, and data validation. 
Dendrite Clinical Systems and the Society for Cardiothoracic Surgery in the UK are pleased to announce the SCTS Conference News 201 newspaper is now available to view/download. This is the third successive year Dendrite has published the newspaper on behalf of the SCTS. The newspaper reports a multitude of presentations from the meeting including the latest and the best information on new technologies and techniques in cardio-thoracic surgery. 
Dendrite Clinical Systems, the publisher of Bariatric News, is pleased to announce issue 35 of the newspaper is now available to view/download. The newspaper reports on research, technology, events and policy in the bariatric specialty, the latest clinical studies, policy changes and product news, the latest meetings and events, interviews prominent bariatric experts, and host debates between specialists on controversial topics.
Dendrite and UK research groups launch MASCOT Registry
Dendrite Clinical Systems – in collaboration with Haemotology Cancer Care (UCLH Charity), the Royal Free Charity, HaemSTAR (an organisation researching non-malignant haematology) and MPN Voice – have launched the MASCOT (Myeloproliferative Neoplasm Splanchnic Vein Thrombosis, MPN-SVT) Registry, a UK wide registry for patients with myeloproliferative diseases suffering from splanchnic or abdominal vein thrombosis.
Myeloproliferative neoplasms are a group of hematopoietic stem cell disorders characterised by clonal proliferation of myeloid-lineage cells. Arterial and venous thromboses are a major cause of morbidity in Ph-negative MPNs. Venous thrombosis may occur at unusual anatomic sites, such as splanchnic vein thrombosis or cerebral sinus thrombosis. SVT refers to thrombosis formation in the portal venous system (portal vein thrombosis, PVT), hepatic venous system Budd-Chiari syndrome (BCS), splenic venous system or mesenteric venous system1.
This prospective web-based patient registry that will collect, record and analyse the treatment and outcomes of patients with this condition.
“We are delighted to launch the MASCOT Registry,” said Dr Peter Walton, Managing Director of Dendrite Clinical Systems. “Myeloproliferative neoplasms are the most common underlying prothrombotic disorder found in patients with splanchnic vein thrombosis and the registry will provide valuable information on how to manage this prothrombotic disorder.
To better understand current practice, this online registry was developed by Dendrite using their “Intellect Web” software. This allows users to enter patient data online, using a range of modern html-5 compatible web browsers, without the need to install additional software or perform any complex system configurations.
Reference
- Ther Adv Hematol. 2017 Mar; 8(3): 107–118.
